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Abstract
Background: We aimed to update the 2010 evidence- and 
consensus-based national clinical guideline on the diagno-
sis and management of uncomplicated urinary tract infec-
tions (UTIs) in adult patients. Results are published in 2 
parts. Part 1 covers methods, the definition of patient 
groups, and diagnostics. This second publication focuses on 
treatment of acute episodes of cystitis and pyelonephritis as 
well as on prophylaxis of recurrent UTIs. Materials and 
Methods: An interdisciplinary group consisting of 17 repre-
sentatives of 12 medical societies and a patient representa-
tive was formed. Systematic literature searches were con-
ducted in MEDLINE, EMBASE, and the Cochrane Library to 
identify literature published in 2010–2015. Results: For the 
treatment of acute uncomplicated cystitis (AUC), fosfomy-
cin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, 
and trimethoprim (depending on the local rate of resis-
tance) are all equally recommended. Cotrimoxazole, fluoro-
quinolones, and cephalosporins are not recommended as 
antibiotics of first choice, for concern of an unfavorable im-
pact on the microbiome. Mild to moderate uncomplicated 
pyelonephritis should be treated with oral cefpodoxime, 
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ceftibuten, ciprofloxacin, or levofloxacin. For AUC with mild 
to moderate symptoms, instead of antibiotics symptomatic 
treatment alone may be considered depending on patient 
preference after discussing adverse events and outcomes. 
Primarily non-antibiotic options are recommended for pro-
phylaxis of recurrent urinary tract infection. Conclusion: In 
accordance with the global antibiotic stewardship initiative 
and considering new insights in scientific research, we up-
dated our German clinical UTI guideline to promote a re-
sponsible antibiotic use and to give clear hands-on recom-
mendations for the diagnosis and management of UTIs in 
adults in Germany for healthcare providers and patients.
© 2018 S. Karger AG, Basel
Background
Uncomplicated, bacterial, community-acquired uri-
nary tract infections (UTIs), including cystitis and pyelo-
nephritis, are among the most common infections in the 
outpatient setting. Antibiotic resistance is a growing 
global problem that leads to significant challenges and 
costs in the health care system [1–4]. We updated the 
German clinical UTI guideline to promote a responsible 
antibiotic use in the management of UTIs in adults in 
Germany.
The German AWMF S3 guideline is free for download 
available in a short and long version on the website of the 
AWMF (Arbeitsgemeinschaft der wissenschaftlichen 
medizinischen Fachgesellschaften) (http://www.awmf.
org/leitlinien/detail/ll/043–044.html) [6]. The category 
S3 refers to the German guideline classification form, 
where S3 represents the highest methodological standard 
and involves both evidence- and consensus-based con-
cept to achieve guideline recommendations from an in-
terdisciplinary panel group [5].
We present the main content of the updated guide-
line in 2 parts. Part I focuses on the recommendations 
regarding the definition of patient groups and the diag-
nostics of uncomplicated bacterial UTI acquired in the 
outpatient setting in adult patients and was already pub-
lished [6]. This publication of part II covers the treat-
ment of acute episodes of cystitis and pyelonephritis as 
well as the prevention of recurrent UTIs (rUTI) in oth-
erwise healthy women in the premenopause (standard 
group). Recommendations concerning other patient’s 
groups are found in the long version of the S3 guideline 
(see above). There is also a German publication avail-
able that covers the latest changes of this guideline up-
date [7].
Objective
We aimed to update the 2010 evidence- and consen-
sus-based national guideline on the diagnostics and man-
agement of uncomplicated UTIs in adult patients. Spe-
cific objectives were (a) to promote a rational use of anti-
microbial substances, (b) to avoid an inappropriate use of 
antibiotic therapies (i.e., use without indication), and (c) 
to avoid the development of antibiotic resistance.
Methods
This AWMF S3 clinical guideline is based on an interdisciplin-
ary consensus group consisting of 17 representatives of 12 medical 
societies and a member of a patient organization  (Table 1). Details 
on the methodological process are described elsewhere [6].
Recommendations are based on a systematic literature search 
that was conducted between 2010 and 2015. The Oxford criteria 
were used for the level of evidence (I-V) ratings [8]. Recommenda-
tions were graded as follows:
A: strong recommendation: should/should not
B: weak recommendation: ought to/ought not to
C: recommendation inconclusive: may be considered.
Results
Figure 1 presents a decision tree on diagnosis and 
treatment in symptomatic patients. The following criteria 
should be taken into account when deciding which anti-
biotic to use (Ia-A):
• Patient’s individual risk
• Spectrum of pathogens and antibiotic sensitivity
• Efficacy of the antimicrobial substance
• Adverse drug reactions
• Effects on the microbiome in the individual patient 
(collateral damage) and/or the general population (ep-
idemiological effects).
Acute Uncomplicated Cystitis: Standard Group 
(Otherwise Healthy Women in the Premenopause)
The spontaneous recovery rate in acute uncomplicated 
cystitis (AUC) is high (at 1 week: clinically 28%, clinically 
and microbiologically 37%). The central goal of treatment 
is swift relief of the clinical symptoms, that is, within a mat-
ter of days [9]. The small number of placebo-controlled 
studies has shown that the symptoms resolve more rapidly 
with antibiotic treatment than with placebo [10]. In a re-
cent study, Gágyor et al. [11] compared the effect of pri-
marily symptomatic ibuprofen treatment with that of im-
mediate administration of an antibiotic. Around two-
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Symptomatic
patient: dysuria,
alguria, pollakisuria,
leukocyturia, fever,
flank pain
Uncomplicated
cystitis of women
with low risk
Other patients, for example,
infection of the upper urinary
tract or complicated UTI
Urine culture with antibiogram
and empiric therapy or
Targeted therapy after availability
of antibiogram
Patient with
special indication,
for example,
pregnancy or
intervention in the
urinary tract
Clinical decision:
definitive case for
therapy
Nitrite positive
urine?
Leukocyte positive
urine?
 Reevaluation of the clinical symptoms
Options according to individual decision:
1. Watchful waiting with/without symptomatic therapy
2. Empiric antibiotic therapy
3. Further evaluation, for example, with gynecological,
 nephrological or urological work-up
No screening for
asymptomatic
bacteriuria
Urine culture with
antibiogram, targeted
therapy after availability
of antibiogram
Empiric therapy
Culture with antibiogram
only if increase in local
resistance pattern to
standard antibiotics
No
No
No
No,
not sureNo
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Fig. 1. Decision tree – diagnosis and treatment in symptomatic patients (clinical-microbiological diagnostic path-
way). On the initial manifestation of acute UTI, or if the patient is unknown to the physician, the medical his-
tory should be documented and a symptom-oriented medical examination carried out.
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thirds of patients with purely symptomatic treatment 
needed no further antibiotic. Meanwhile, in another recent 
study, a symptomatic treatment with non-steroidal anti-
inflammatory drugs was compared with immediate antibi-
otic therapy. Rate of antibiotic prescriptions could also be 
reduced significantly [12]. In light of these findings, non-
antibiotic, symptomatic treatment can be considered in 
cases of AUC with mild or moderate symptoms (IA-B). 
Due consideration should be paid to the patients’ prefer-
ences when deciding what course of treatment to follow. 
This is especially true for primarily non-antibiotic treat-
ment, which may be associated with a greater burden of 
symptoms (symptom-free after 7 days: ibuprofen 163 of 
232 patients versus fosfomycin 186 of 227 patients, 95% CI 
[–19.4 to –4.0]) [11]. Patients’ preferences have to be taken 
into account and the decision should be made after dis-
cussing adverse events and outcomes.
Asymptomatic Bacteriuria
In general, asymptomatic bacteriuria (ASB) does nei-
ther need screening nor treatment. The presence of ASB, 
however, increases the risk of infection for patients under-
going urinary tract interventions in which mucosal trauma 
can be anticipated. Therefore, in such cases, ASB should be 
actively sought, and if present, it should be treated (Ia-A) 
[13]. The evidence from randomized studies in this respect 
exists primarily for transurethral resection of the prostate. 
However, high level evidence is lacking regarding low-risk 
interventions, for example, urethrocystoscopy.
Kazemier et al. [14] showed that in women low-risk 
pregnancy and ASB the risk of symptomatic cystitis in-
creased from 7.9 to 20.2% if they were treated with pla-
cebo or not at all (for pyelonephritis from 0.6 to 2.4%). 
However, ASB did not increase the risk of premature 
birth for non-treated patients [14].
Table 1. Participating medical societies and working groups
Medical society or working group Participants in the update 2017
German Society of Urology (DGU) – lead organization Dr. Jennifer Kranz
Prof. Dr. Kurt Naber
Dr. Stefanie Schmidt
Dr. Laila Schneidewind
Priv. Doz. Dr. Winfried Vahlensieck
Prof. Dr. Florian M. Wagenlehner
German College of General Practitioners and Family Physicians (DEGAM) Prof. Dr. E. Hummers
Priv.-Doz. Dr. Guido Schmiemann
German Society of Gynecology and Obstetrics (DGGG) Prof. Dr. U. Hoyme
Dr. Mirjam Kunze
German Society for Hygiene and Microbiology (DGHM) Dr. E. Kniehl
German Society of Infectious Diseases (DGI) Dr. Sina Helbig
Dr. Falitsa Mandraka
German Society of Nephrology (DGfN) Prof. Dr. R. Fünfstück
Prof. Dr. U. Sester
Paul Ehrlich Society for Chemotherapy (PEG) Prof. Dr. R. Fünfstück
Dr. E. Kniehl
Prof. Dr. Kurt Naber
Prof. Dr. Florian M. Wagenlehner
German Society for Clinical Chemistry and Laboratory Medicine (DGKL) Prof. Dr. W. Hofmann
German Association of Pharmacists (AKDA) Dr. Cordular Lebert
Patient representative, Interstitielle Cystitis Association Deutschland (ICA-D) B. Mündner-Hensen
DGU, Deutsche Gesellschaft für Urologie; DEGAM, Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin; DGHM, 
Deutsche Gesellschaft für Hygiene und Mikrobiologie; DGI, Deutsche Gesellschaft für Infektiologie; DGfN, Deutsche Gesellschaft 
für Nephrologie; PEG, Paul-Ehrlich-Gesellschaft für Chemotherapie; DGKL, Deutsche Gesellschaft für Klinische Chemie und 
 Laboratoriumsmedizin.
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General Comment on Antibiotic Treatment of AUC
Among the group of antibiotics or classes of antibiotic 
drugs that are basically suitable for the treatment of 
AUC – aminopenicillins in combination with a beta-lac-
tamase inhibitor, groups 2 and 3 cephalosporins, fluoro-
quinolones, fosfomycin-trometamol, nitrofurantoin, ni-
troxoline, pivmecillinam, trimethoprim, or cotrimoxa-
zole – the fluoroquinolones and cephalosporins are 
associated with the greatest risk of microbiological col-
lateral damage by selection of multiple drug resistant 
pathogens or an elevated risk of Clostridium difficile-as-
sociated colitis [15]. 
Since fluoroquinolones and cephalosporins have an 
important role in the treatment of complicated infec-
tions, the clinical consequences of increased resistance 
by their use in uncomplicated infections were rated as 
more severe than for other antibiotics recommended 
for the treatment of AUC (V). Therefore, fluoroquino-
lones and cephalosporins should not be used in the 
treatment of AUC unless there is no alternative (V-A; 
Table 2). Cotrimoxazole is also not recommended, be-
cause it is not more efficacious than trimethoprim 
mono, but exhibits a higher rate of adverse events. In 
addition, patient-relevant clinical endpoints (clinical 
improvement of symptoms, recurrences, ascending in-
fections) and the individual risk (e.g., tendon rupture 
with the fluoroquinolones) should be taken into ac-
count.
Acute Uncomplicated Pyelonephritis: Standard Group
Patients with acute uncomplicated pyelonephritis 
(AUP) should receive efficacious antibiotic treatment as 
soon as possible, because of possible kidney damage 
[16], which is more likely with increasing duration, and 
severity of pyelonephritis. In choosing the best antibi-
otic to use, the eradication rates, sensitivity, collateral 
damage, and special characteristics regarding adverse 
drug reactions should be taken into account (V; Table 
Table 2. Recommended empirical short-term antibiotic treatment of uncomplicated cystitis in women in the premenopause (standard 
group; listing in alphabetic order)
Substance Daily dose Duration, 
days
Eradication rate 
in sensitive pathogens
Sensitivity Collateral 
damage
Safety/ADR
The following antibiotics should be used preferentially in the treatment of uncomplicated cystitis
Fosfomycin-trometamol 3,000 mg 1 × daily 1 ++ +++ +++ +++
Nitrofurantoin 50 mg 4 × daily 7 +++ +++ +++ ++
Nitrofurantoin RT 
(slow-release form) 100 mg 2 × daily 5 +++ +++ +++ ++
Nitroxolin 250 mg 3 × daily 5 +++ +++ +++ +++
Pivmecillinam 400 mg 2–3 × daily 3 +++ +++ +++ +++
Trimethoprim should not be used as drug of first choice if local resistance to E. coli is >20%
Trimethoprim 200 mg 2 × daily 3 +++ +(+) ++ ++(+)
The following antibiotics should not be used as drugs of first choice in the treatment of uncomplicated cystitis
Cefpodoxim-proxetil 100 mg 2 × daily 3 ++ ++ + +++
Ciprofloxacin 250 mg 2 × daily 3 +++ ++ + ++
Cotrimoxazol 160/800 mg 2 × daily 3 +++ +(+) ++ ++
Levofloxacin 250 mg 1 × daily 3 +++ ++ + ++
Norfloxacin 400 mg 2 × daily 3 +++ ++ + ++
Ofloxacin 200 mg 2 × daily 3 +++ ++ + ++
Symbol Eradication, % Sensitivity, % Collateral damage Safety/ADR
+++ >90 >90 Little selection of multiple drug resistant pathogens, little 
development of resistance to own class of antibiotics
High safety, slight ADR
++ 80–90 80–90 Little selection of multiple drug resistant pathogens, 
 development of resistance to own class of antibiotics
Severe ADR possible
+ <80 <80 Selection of multiple drug resistant pathogens,  
 development of resistance to own class of antibiotics
n.a.
ADR, adverse drug reactions.
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3). As the prevalence is much lower than that of AUC 
(0.16%) [17], less heed has to be paid to collateral dam-
age [17].
Prevention of Recurrent Urinary Tract Infection: 
Standard Group
Before initiation of long-term prophylactic drug 
treatment, a woman with rUTI should be counseled in 
detail on avoidance of risks (e.g., not drinking enough, 
overcooling, excessive intimate hygiene; Ib-A) [18, 19]. 
If rUTI persists despite appropriate preventive mea-
sures, long-term non-antibiotic prophylaxis ought to be 
preceded by oral administration of an Escherichia coli 
lysate (OM-89) for 3 months (Ia-B) [20]. Immunopro-
phylaxis by means of 3 parenteral injections of inacti-
vated specified enterobacteria at 1-week intervals can be 
used (Ib-C) [14]. Moreover, mannose can be recom-
mended (Ib-C) [21]; alternatively, various phytothera-
peutic agents (bearberry leaves with dandelion root and 
horseradish root with nasturtium herb proven in stud-
ies) may be considered (Ib-C) [22, 23]. If the patient’s 
level of suffering is high, failure of behavioral modifica-
Table 3. Recommended empirical antibiotic treatment of uncomplicated pyelonephritis in women in the premenopause (standard group)
Substance Daily dose Duration, 
days
Eradication 
rate in sensitive
pathogens
Sensitivity Collateral 
damage
Safety/ADR
Oral treatment in mild to moderate infection
Ciprofloxacin1 500–750 mg 2 × daily 7–10 +++ ++ + ++
Levofloxacin 750 mg 1 × daily 5 +++ ++ + ++
Cefpodoxim-proxetil 200 mg 2 × daily 10 +++ ++ + +++
Ceftibuten2 400 mg 1 × daily 10 +++ ++ + +++
Initial parenteral therapy in severe infection
Following improvement, in the presence of pathogen sensitivity oral sequential treatment with one of the above-mentioned oral 
agents can be initiated. The total duration of treatment is 1–2 weeks; therefore, no duration of treatment is given for the parenteral 
antibiotics
First-choice drugs
Ciprofloxacin 400 mg (2)–3 × daily +++ ++ + ++
Levofloxacin 750 mg 1 × daily +++ ++ + ++
Ceftriaxon1, 3 (1)–2 g 1 × daily +++ ++ + +++
Cefotaxim4 2 g 3 × daily +++ ++ + +++
Second-choice drugs
Amoxicillin/clavulanic acid4, 5 2.2 g 3 × daily ++ + +++ +++
Amikacin 15 mg/kg 1 × daily ++ ++ ++ +(+)
Gentamicin 5 mg/kg 1 × daily ++ ++ ++ +(+)
Cefepime1 ,3 (1)–2 g 2 × daily +++ ++ + +++
Ceftazidime2 (1)–2 g 3 × daily +++ ++ + +++
Ceftazidime/avibactam 2.5 g 3 × daily +++ +++ ++ +++
Ceftolozan/tazobactam 1.5 g 3 × daily +++ +++ ++ +++
Piperacillin/tazobactam1, 3 4.5 g 3 × daily +++ +++ ++ +++
Ertapenem3, 6 1 g 1 × daily +++ +++ ++ +++
Imipenem/cilastatin1, 3, 6 1 g/1 g 3 × daily +++ +++ ++ +++
Meropenem3, 6, 7 1 g 3 × daily +++ +++ ++ +++
1 Low dosage investigated, high dosage recommended by experts. 
2 No longer on sale in Germany.
3 Same protocol for acute uncomplicated pyelonephritis and complicated urinary tract infection (stratification not always possible).
4 Not investigated as sole substance in acute uncomplicated pyelonephritis.
5 Principally for gram-positive pathogens. 
6 Only in extended-spectrum betalactamase resistance >10%.
7 Only high dosages investigated. Symbols as explained in Table 2.
ADR, adverse drug reactions.
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tion and non-antibiotic prophylaxis ought to be fol-
lowed by continual long-term antibiotic prophylaxis for 
3–6 months (IV-B) [17] (Table 4). In the presence of an 
association with sexual intercourse, postcoital prophy-
laxis with a single dose ought to be used instead of long-
term administration of antibiotics (Ib-B) [17, 24, 25].
Conclusion
The high frequency of uncomplicated bacterial com-
munity-acquired UTIs in adults and their treatment and 
prophylaxis with antibiotics exerts massive antibiotic se-
lection pressure on the microbiome, resulting in signifi-
cant influence on the selection of antibiotic-resistant bac-
teria in the population. Rational use of antibiotics for this 
indication is therefore prudent in safeguarding the effi-
cacy of antibiotic treatment (antibiotic stewardship). The 
evidence and consensus-based recommendations of the 
updated S3 guideline therefore need to be widely imple-
mented.
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